Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | polo-like kinase 1 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | CAMK family protein kinase | 0.0114 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0071 | 0.3108 | 0.3108 |
Trypanosoma brucei | polo-like protein kinase | 0.0114 | 1 | 0.5 |
Echinococcus multilocularis | serine:threonine protein kinase PLK1 | 0.0114 | 1 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0114 | 1 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0114 | 1 | 1 |
Loa Loa (eye worm) | PLK/PLK1 protein kinase | 0.0114 | 1 | 1 |
Trypanosoma cruzi | polo-like protein kinase, putative | 0.0114 | 1 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0114 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0114 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0071 | 0.3108 | 0.2373 |
Echinococcus granulosus | serine:threonine protein kinase PLK1 | 0.0114 | 1 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0071 | 0.3108 | 0.2373 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0114 | 1 | 1 |
Giardia lamblia | Kinase, PLK | 0.0114 | 1 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0114 | 1 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0114 | 1 | 1 |
Leishmania major | protein kinase, putative,polo-like protein kinase, putative | 0.0114 | 1 | 0.5 |
Trypanosoma cruzi | polo-like protein kinase, putative | 0.0114 | 1 | 0.5 |
Entamoeba histolytica | serine/threonine protein kinase, putative | 0.0114 | 1 | 1 |
Onchocerca volvulus | Serine\/threonine kinase homolog | 0.0114 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.6964 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 10.6213 uM | PubChem BioAssay. qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PUBCHEM_BIOASSAY: Inhibitors of the vitamin D receptor (VDR): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504855] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.